Introduction {#ene13919-sec-0005}
============

Clinically, Parkinson\'s disease (PD) has been defined by the presence of motor deficits such as bradykinesia, tremor, rigidity and postural instability [1](#ene13919-bib-0001){ref-type="ref"}. However, patients with PD also experience a variety of other non‐motor symptoms (NMS) such as mood disorders, autonomic disturbances, cognitive impairment and sleep dysfunction throughout their disease trajectory.

Non‐motor symptoms can precede motor symptoms, indicating that a prodromal symptomatic stage exists in PD. The presence of hyposmia, constipation, depression and idiopathic rapid eye movement sleep behaviour disorder are well‐established symptoms that significantly increase the risk of development of PD [2](#ene13919-bib-0002){ref-type="ref"}.

The emerging concept of a prodromal phase of PD has led the International Parkinson and Movement Disorder Society task force to propose a new definition of PD; this definition would not base the diagnosis solely on motor symptoms but would also incorporate NMS [3](#ene13919-bib-0003){ref-type="ref"}. However, there is a paucity of research investigating the frequency and time of onset of NMS before the onset of the motor phase of PD. Furthermore, little is known about the relationship between particular clusters of prodromal NMS (pNMS) and the development of subsequent PD motor phenotypes, i.e. tremor dominant (TD), postural instability gait difficulty (PIGD) or indeterminate type [4](#ene13919-bib-0004){ref-type="ref"}.

We aimed to explore the frequency and time of onset of NMS before motor symptoms (pNMS) and the role of gender on pNMS experienced. We hypothesized that distinct clusters of pNMS would be associated with PIGD motor phenotype.

Methods {#ene13919-sec-0006}
=======

Patient eligibility criteria and recruitment {#ene13919-sec-0007}
--------------------------------------------

Patients with recently diagnosed PD from Newcastle upon Tyne and Gateshead were invited to take part in the study between June 2009 and December 2011 as part of the Incidence of Cognitive Impairment in Cohorts with Longitudinal Evaluation‐Parkinson\'s Disease (ICICLE‐PD) study [5](#ene13919-bib-0005){ref-type="ref"}.

All participants were diagnosed by a movement disorders specialist according to the UK Brain Bank criteria [1](#ene13919-bib-0001){ref-type="ref"}. Exclusion criteria comprised the following: drug‐induced parkinsonism secondary to exposure to dopamine receptor blocking agent at the onset of symptoms; vascular parkinsonism; and atypical forms of parkinsonism such as progressive supranuclear palsy, multiple system atrophy or corticobasal degeneration, according to accepted diagnostic criteria [6](#ene13919-bib-0006){ref-type="ref"}. Participants were also excluded if they had insufficient working knowledge of English, defined as being unable to perform the assessments and questionnaires in the opinion of the assessor, or significant memory impairment or dementia at presentation, defined by a Mini‐Mental State Examination score \<24, fulfilling DSM‐IV criteria for dementia [7](#ene13919-bib-0007){ref-type="ref"} or Movement Disorder Society criteria for Parkinson's disease dementia [8](#ene13919-bib-0008){ref-type="ref"}.

The study was approved by the Newcastle and North Tyneside Research Ethics Committee and performed according to the Declaration of Helsinki. All participants provided informed written consent.

Assessments {#ene13919-sec-0008}
-----------

Participants with PD were rated for disease severity by Hoehn & Yahr staging and motor severity using the Movement Disorder Society Unified Parkinson\'s Disease Rating Scale part III. Motor subtypes were defined as TD, PIGD and indeterminate type according to the methods described by Stebbins *et al*. [9](#ene13919-bib-0009){ref-type="ref"}. Due to the small numbers with indeterminate motor phenotype in the cohort, only comparisons between motor subtype of TD and PIGD were conducted. Levodopa equivalent daily dose (LEDD) was calculated for all dopaminergic medications using methods described by Tomlinson *et al*. [10](#ene13919-bib-0010){ref-type="ref"}.

Global cognition was assessed using the Mini‐Mental State Examination and Montreal Cognitive Assessment. Depressive symptoms were also assessed using the Geriatric Depression Scale‐15.

Assessment of non‐motor symptoms and prodromal non‐motor symptoms {#ene13919-sec-0009}
-----------------------------------------------------------------

Participant NMS burden was assessed at the initial patient screening visit using the Non‐Motor Symptom Questionnaire (NMSQuest) [11](#ene13919-bib-0011){ref-type="ref"}. The NMSQuest is a 30‐item questionnaire that comprises 10 domains of NMS: gastrointestinal (GI) symptoms, urinary tract symptoms, sexual function, cardiovascular issues, depression/anxiety, sleep problems/fatigue, pain and a number of other complaints such as weight loss. A positive response about the presence of an NMS on the screening questionnaire elicited a further question about the estimated duration of the NMS symptom.

In order to determine the presence or absence of pNMS, we subtracted the duration of the presence of each individual NMS reported from the duration of earliest motor symptom. NMS whose duration preceded the duration of motor symptoms were considered a pNMS, whereas NMS that occurred after motor symptom onset were not classified as pNMS. The presence and duration of each NMS in excess of the duration of motor symptoms were recorded as a pNMS in months.

Individual pNMS symptoms were further classified into seven distinct non‐motor subtypes based on the symptom domains covered in the NMSQuest. These were GI symptoms, urinary tract symptoms, sexual dysfunction, cardiovascular symptoms, neuropsychiatric and cognitive symptoms, sleep dysfunction symptoms and miscellaneous symptoms. In order to be included in a prodromal non‐motor subtype, a participant had to have at least one pNMS consistent with that NMS domain.

Statistical analysis {#ene13919-sec-0010}
--------------------

Statistical analyses were performed using SPSS software (Version 22, IBM Corp., Armonk, NY, USA). Data were assessed for normality using Kolmogorov--Smirnov tests. The mean and SD were computed for parametric variables, and the median and interquartile range for non‐parametric variables. Continuous and count data were compared using the parametric (*t*‐test) or non‐parametric (Mann--Whitney *U*‐test) test as appropriate and categorical data were compared with chi‐squared tests.

Hierarchical logistic regression was used to determine significant predictors of PIGD motor phenotype. Backwards stepwise logistic regression was used to produce a basic model of predictors involving age, gender and LEDD. Non‐significant predictors were excluded. Significant predictors were then included to give a basic model and total pNMS and pNMS domains (present or absent) were then individually added to the model. *P* \< 0.05 was deemed to be significant for all analyses.

Results {#ene13919-sec-0011}
=======

A total of 154 participants with a diagnosis of idiopathic PD were identified from the ICICLE‐PD cohort (Table [1](#ene13919-tbl-0001){ref-type="table"}). Participants had a mean age of 66.4 ± 10.4 years and had a median PD duration of 4.7 months \[64.9% (*n* = 100) were male}.

###### 

Characteristics of patients with Parkinson\'s disease (PD) (*n* = 154)

  Variable                                            
  --------------------------------------------------- ----------------------
  Gender (male/female)                                100 (64.9)/54 (35.1)
  Age (years)                                         66.4 (10.4)
  Duration of PD (months)                             4.7 (2.6--8.1)
  MDS‐UPDRS III score                                 26.9 ± 12.1
  H&Y staging                                         2.0 ± 0.7
  H&Y stage                                           
  I                                                   35 (22.7)
  II                                                  88 (57.1)
  III                                                 30 (19.5)
  IV                                                  1 (0.6)
  V                                                   0
  PD medication treatment                             
  Drug naive                                          19 (12.3)
  Levodopa                                            45 (29.2)
  Dopaminergic agonists                               57 (37)
  MAOB inhibitor                                      73 (47.4)
  LEDD (mg/day)                                       178.1 ± 148.2
  Motor phenotype                                     
  PIGD                                                78 (50.6)
  Indeterminate                                       13 (8.4)
  TD                                                  63 (40.9)
  MMSE score                                          28.6 ± 1.3
  MoCA score[a](#ene13919-note-0001){ref-type="fn"}   25.2 ± 3.7
  GDS‐15 score                                        2.8 ± 2.6

GDS‐15, Geriatric Depression Scale‐15; H&Y, Hoehn & Yahr; LEDD, levodopa equivalent daily dose; MAOB, monoamine oxidase B; MDS‐UPDRS, Movement Disorder Society Unified Parkinson\'s Disease Rating Scale, revised; MMSE, Mini‐Mental State Examination; MoCA, Montreal Cognitive Assessment; PIGD, postural instability gait difficulty motor subtype; TD, tremor dominant motor subtype. Data are given as mean ± SD, *n* (%) and median (interquartile range). ^a^MoCA completed in 140 patients with PD.
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The presence or absence of pNMS was calculated \[139 (90.3%) participants experienced pNMS\] (Table [2](#ene13919-tbl-0002){ref-type="table"}). The median number of pNMS experienced by the patients with PD was 4 (interquartile range, 2--7). The most common individual pNMS experienced were as follows: hyposmia (39.6%), forgetfulness/memory complaints (36%), sialorrhea (33.8%), urinary urgency (30.2%) and anxiety (30.2%) (Table [2](#ene13919-tbl-0002){ref-type="table"}). Gender differences in pNMS experienced were observed, with males reporting significantly more sexual dysfunction (22% vs. 3.7%, respectively, *P* = 0.003), forgetfulness (38% vs. 22.2%, respectively, *P* = 0.046) and dream re‐enactment (29% vs. 14.8%, respectively, *P* = 0.049) compared with female participants (Table [2](#ene13919-tbl-0002){ref-type="table"}). Conversely, females reported significantly greater unexplained weight change (13% vs. 4%, respectively, *P* = 0.039) and anxiety (37% vs. 22%, respectively, *P* = 0.046).

###### 

Prevalence of non‐motor symptoms (NMS) at screening and prodromal NMS (pNMS) in patients with Parkinson\'s disease (PD) and median duration before the development of motor symptoms

                                          pNMS (*n* = 154)   Time interval of NMS preceding motor symptoms (months)   pNMS in males vs. females                                  
  --------------------------------------- ------------------ -------------------------------------------------------- --------------------------- ----------- ------------------ -------
  No. of patients with PD with symptoms   139 (90.3)                                                                                                                             
  No pNMS experienced                     4 (2--7)                                                                    4 (2--6.25)                 4 (2--7)    *U* = 2850.5       0.649
  Gastrointestinal tract                                                                                                                                                         
  Sialorrhea                              47 (30.5)          −33 (−18 to −3)                                          34 (34)                     13 (24.1)   *χ* ^2^ = 1.6      0.202
  Dysphagia                               18 (11.7)          −25 (−27 to −4)                                          11 (11)                     7 (13)      *χ* ^2^ = 0.1      0.718
  Nausea                                  3 (1.9)            −25 (−48 to −24)                                         1 (1)                       2 (3.7)     *χ* ^2^ = 1.3      0.247
  Constipation                            38 (24.7)          −108 (−105 to −11)                                       24 (24)                     14 (25.9)   *χ* ^2^ = 0.1      0.791
  Bowel incontinence                      4 (2.6)            −175 (−516 to −1)                                        2 (5)                       2 (3.7)     *χ* ^2^ = 0.4      0.526
  Incomplete bowel emptying               26 (16.9)          −55 (−31 to −6)                                          17 (17                      9 (16.7)    *χ* ^2^ = \<0.1    0.958
  Hyposmia                                55 (35.7)          −148 (−218 to −26)                                       32 (32.0)                   23 (42.6)   *χ* ^2^ = 1.7      0.191
  Weight change (unexplained)             11 (7.1)           −13 (−12 to −1)                                          4 (4.0)                     7 (13.0)    *χ* ^2^ = 4.2      0.039
  Urinary tract                                                                                                                                                                  
  Urinary urgency                         42 (27.3)          −63 (−65 to −12)                                         25 (25)                     17 (31.5)   *χ* ^2^ = 0.7      0.389
  Nocturia                                29 (18.8)          −82 (−78 to −12)                                         18 (18)                     11 (20.4)   *χ* ^2^ = 0.1      0.72
  Sexual function                                                                                                                                                                
  Sexual dysfunction                      24 (15.6)          −89 (−87 to −22)                                         22 (22.0)                   2 (3.7)     *χ* ^2^ = 8.9      0.003
  Impaired libido                         15 (9.7)           −56 (−96 to −18)                                         12 (12)                     3 (5.6)     *χ* ^2^ = 1.7      0.198
  Cardiovascular                                                                                                                                                                 
  Orthostatic symptoms                    28 (18.2)          −23 (−31 to −2)                                          20 (20.0)                   8 (14.8)    *χ* ^2^ = 0.6      0.426
  Falls                                   16 (10.4)          −13 (−12 to −2)                                          11 (11.0)                   5 (9.3)     *χ* ^2^ = 0.1      0.735
  Lower limb swelling                     17 (11.0)          −61 (−75 to −8)                                          10 (10.0)                   7 (13.0)    *χ* ^2^ = 0.3      0.576
  Neuropsychiatric and cognitive                                                                                                                                                 
  Forgetfulness/memory                    50 (32.5)          −36 (−36 to −8)                                          38 (38)                     12 (22.2)   *χ* ^2^ = 4.0      0.046
  Impaired concentration                  25 (16.2)          −37 (−33 to −8)                                          16 (16.0)                   9 (16.7)    *χ* ^2^ = \<0.11   0.915
  Anxiety                                 42 (27.3)          −99 (−36 to −12)                                         22 (22.0)                   20 (37.0)   *χ* ^2^ = 4.0      0.046
  Low mood                                27 (17.5)          −20 (−31 to −7)                                          15 (15)                     12 (22.2)   *χ* ^2^ = \<0.1    0.261
  Loss of interest/apathy                 22 (14.3)          −20 (−25 to −8)                                          13 (13)                     9 (16.7)    *χ* ^2^ = 0.4      0.535
  Delusions                               0 (0)              NA                                                       0 (0) NA                    0 (0)       NA                 NA
  Visual hallucinations                   12 (7.8)           −12 (−17 to −4)                                          7 (7.0)                     5 (9.3)     *χ* ^2^ = 0.2      0.618
  Sleep                                                                                                                                                                          
  Daytime somnolence                      32 (20.8)          −68 (−79 to −12)                                         25 (25)                     7 (13)      *χ* ^2^ = 3.1      0.079
  Insomnia                                10 (6.5)           −28 (−51 to −11)                                         5 (5)                       5 (9.3)     *χ* ^2^ = 1.0      0.306
  Dream re‐enactment                      37 (24.0)          −167 (−178 to −16)                                       29 (29.0)                   8 (14.8)    *χ* ^2^ = 3.9      0.049
  Vivid dream imagery                     35 (22.7)          −175 (−228 to −12)                                       25 (25.0)                   10 (18.5)   *χ* ^2^ = 0.8      0.36
  Restless legs                           28 (18.2)          −70 (−49 to −6)                                          14 (14.0)                   14 (25.9)   *χ* ^2^ = 3.4      0.067
  Miscellaneous                                                                                                                                                                  
  Diplopia                                11 (7.1)           −112 (−109 to−19)                                        6 (6.0)                     5 (9.3)     *χ* ^2^ = 0.6      0.454
  Hyperhydrosis                           4 (2.6)            −48 (−93 to−11)                                          1 (1.0)                     3 (5.6)     *χ* ^2^ = 2.9      0.090
  Pain (unexplained)                      32 (20.8)          −15 (−23 to−6)                                           17 (17)                     15 (27.8)   *χ* ^2^ = 2.4      0.116

NA, not applicable. Data are given as *n* (%) and median (interquartile range).
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Individual pNMS symptoms were classified into pNMS domains. The most frequent pNMS domains were GI tract (67.5%), sleep (52.6%), urinary tract (42.2%), cardiovascular system (32.5%) and miscellaneous systems (22.1%) (Table [3](#ene13919-tbl-0003){ref-type="table"}). In terms of the median duration of pNMS preceding motor symptom onset, sleep dysfunction (−66 months), sexual dysfunction (−60 months) and GI tract symptoms (−59  months) had the longest latency period (Table [3](#ene13919-tbl-0003){ref-type="table"}). When pNMS were grouped into symptom clusters, males experienced significantly more symptoms related to sexual problems compared with female participants (26% vs. 5.6%, respectively, *P* = 0.002, Table [3](#ene13919-tbl-0003){ref-type="table"}). Females experienced significantly more miscellaneous symptoms compared with male participants (40.7% vs. 19%, respectively, *P* = 0.004).

###### 

Prevalence and median duration of prodromal non‐motor symptoms (pNMS) according to distinct pNMS domains

  Symptom group                    PD pNMS      Time interval of NMS preceding motor symptoms (months)   pNMS in males vs. females                       
  -------------------------------- ------------ -------------------------------------------------------- --------------------------- ----------- ------- -------
  Gastrointestinal tract           104 (67.5)   −58.5 (−217 to −16)                                      67 (67.0)                   37 (68.5)   \<0.1   0.848
  Urinary tract                    65 (42.2)    −45 (−126 to −14)                                        38 (38.0)                   20 (37.0)   \<0.1   0.906
  Sexual function                  32 (20.8)    −60 (−119 to −29)                                        26 (26.0)                   3 (5.6)     9.6     0.002
  Cardiovascular                   50 (32.5)    −12 (−48 to −5)                                          35 (35.0)                   15 (27.8)   0.8     0.361
  Neuropsychiatric and cognitive   19 (12.3)    −39 (−132 to−14)                                         55 (55)                     30 (55.6)   \<0.1   0.947
  Sleep                            81 (52.6)    −66 (−237 to −19)                                        55 (55.0)                   25 (46.3)   1.1     0.302
  Miscellaneous                    34 (22.1)    −12 (−48 to −8)                                          19 (19.0)                   22 (40.7)   8.5     0.004

NMS, non‐motor symptoms; PD, Parkinson\'s disease. Data are given as *n* (%) and median (interquartile range).
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Prodromal NMS differences between motor phenotypes were then evaluated (Table [4](#ene13919-tbl-0004){ref-type="table"}). Participants classified as having PIGD were significantly older than those with TD subtypes (68.4 ± 9.2 vs. 63.6 ± 11 years, respectively, *P* = \<0.01; Table [4](#ene13919-tbl-0004){ref-type="table"}). The Geriatric Depression Scale‐15 scores were slightly higher for the PIGD subtype compared with the TD subtype (3.12 ± 2.4 vs. 2.27 ± 2.3, respectively, *P* = 0.01), but were still below the cut‐off (≥5) for possible depression in all subtypes. Participants with PIGD subtype were prescribed significantly higher doses of LEDD compared with TD subtype (203.0 ± 138.6 mg vs. 151.4 ± 165.4 mg, respectively, *P* \< 0.01; Table [4](#ene13919-tbl-0004){ref-type="table"}).

###### 

Demographics and prevalence of prodromal non‐motor symptoms among Parkinson\'s disease (PD) motor subtypes

  Variable                                            PIGD (*n* = 78)      TD (*n* = 63)         Test statistic   *P*‐value
  --------------------------------------------------- -------------------- --------------------- ---------------- -----------
  Gender (male/female)                                56 (71.8)/22(28.2)   36 (57.1)/27 (42.9)   *χ* ^2^ = 3.3    0.069
  Age (years)                                         68.4 (9.2)           63.6 (10.97)          *t* = 2.7        **0.007**
  Duration of PD (months)                             6.2 (4.8)            5.7 (4.4)             *U* = 2376.0     0.737
  LEDD (mg/day)                                       203.04 ± 138.61      151.4 ± 165.4         *U* = 1684.5     **0.001**
  MMSE score                                          28.53 (1.3)          28.8 (1.3)            *U* = 2081.0     0.106
  MoCA score[a](#ene13919-note-0004){ref-type="fn"}   24.77 (3.6)          25.6 (3.7)            *U* = 1709.0     0.117
  GDS‐15 score                                        3.12 (2.4)           2.3 (2.3)             *U* = 1849.5     **0.011**
  MDS‐UPDRS III score                                 26.96 (12.1)         26.2 (12.1)           *U* = 2315.0     0.556

GDS‐15, Geriatric Depression Scale‐15; LEDD, levodopa equivalent daily dosage; MDS‐UPDRS, Movement Disorder Society Unified Parkinson\'s Disease Rating Scale, revised; MMSE, Mini‐Mental State Examination; MoCA, Montreal Cognitive Assessment; PIGD, postural instability gait difficulty motor subtype; TD, tremor dominant motor subtype. Data are given as mean ± SD and *n* (%) unless otherwise stated. Significant results are highlighted in bold. ^a^MoCA completed in 140 patients with PD.
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Predictors of PIGD motor phenotype were then determined, first using logistic univariate regression. Significant predictors included age, LEDD, Geriatric Depression Scale‐15 score, number of pNMS, GI symptoms and urinary symptoms (Table S1).

Backwards regression revealed that only age \[*β* = 0.061; odds ratio (OR), 1.06; 95% confidence interval (CI), 1.02--1.11, *P* = 0.003\] was a significant predictor of PIGD phenotype; a basic model was then constructed with age and LEDD. LEDD was included in the basic model as it was an important confounding variable although it was not a significant predictor of PIGD phenotype. Total pNMS and pNMS domains were then individually added to the model. Analysis revealed that total pNMS was not a significant predictor of having PIGD phenotype (OR, 1.10; 95% CI, 0.99--1.21 *P* \> 0.05). However, there was a significant association between any prodromal GI symptoms (OR, 2.30; 95% CI, 1.08--4.89, *P* \< 0.05) and urinary symptoms (OR, 2.54; 95% CI, 1.19--5.35, *P* \< 0.05) and the PIGD phenotype. Patients with PD with prodromal GI symptoms were thus 2.3 times more likely to develop PIGD phenotype, after controlling for age and LEDD. Similarly, participants with PD with prodromal urinary symptoms were 2.5 times more likely to evolve into a PIGD rather than TD phenotype, after controlling for age and LEDD (Supporting Information).

Discussion {#ene13919-sec-0012}
==========

Our study strengthens the notion of NMS antedating motor symptoms in PD by assessing the presence and time of onset of the full spectrum of pNMS using a validated NMS questionnaire (NMSQuest) in a population with recently diagnosed PD. Interpretation of previous studies evaluating the frequency and duration of onset of pNMS is limited by study methodological variability, lack of direct patient evaluation [2](#ene13919-bib-0002){ref-type="ref"}, long duration from PD diagnosis to study enrolment [12](#ene13919-bib-0012){ref-type="ref"}, utilization of non‐validated, custom‐made NMS questionnaires [13](#ene13919-bib-0013){ref-type="ref"} or studying only limited subsets of the spectrum on pNMS in PD cohorts [14](#ene13919-bib-0014){ref-type="ref"} or 'at risk' of PD cohorts [15](#ene13919-bib-0015){ref-type="ref"}, [16](#ene13919-bib-0016){ref-type="ref"}.

Our study found 90% of participants reporting at least one pNMS, whereas the median number of pNMS experienced was four. Previous studies have reported higher prevalence of prodromal symptoms than our study, probably due to methodological differences. A retrospective study conducted via telephone interview with patients with PD and controls, using a custom‐made questionnaire, reported 98.9% of subjects with PD having one or more prodromal symptoms but this study incorporated prodromal motor symptoms as well as pNMS [2](#ene13919-bib-0002){ref-type="ref"}. Similarly, another retrospective study, with a long mean duration from PD diagnosis of 7.6 ± 5.6 years, reported 98.9% of subjects experienced prodromal symptoms preceding a diagnosis of PD [12](#ene13919-bib-0012){ref-type="ref"}.

Based on the Braak model of the hypothesized spread of alpha‐synuclein in PD, alpha synuclein accumulation begins in the gut before progressing via the vagus nerve to the brain [17](#ene13919-bib-0017){ref-type="ref"}. Therefore, GI features should be a prominent early manifestation of PD. Our study encompassed questions focusing on the GI tract that had not been previously reported, such as the prevalence of prodromal weight loss (7.1%), dysphagia (11.7%) and incomplete bowel emptying (16.9%). Prevalence of prodromal constipation symptoms (24.7%) and hyposmia (35.7%) have previously been reported and are approximately in line with published work [2](#ene13919-bib-0002){ref-type="ref"}, [13](#ene13919-bib-0013){ref-type="ref"}. Clustering prodromal GI symptoms together revealed that 67.5% of subjects with PD had one or more GI symptoms antedating motor symptom development in PD, which is consistent with the Braak model of early GI involvement in PD. Moreover, GI clusters, as well as urinary tract clusters, of pNMS were significantly associated with PIGD motor phenotype. To the best of our knowledge, no other study has shown an association between pNMS clusters and early PD motor phenotype.

In contrast with other studies, the prevalence of prodromal memory complaints (32.8%) and unexplained pain (20.8%) in our study is substantially higher compared with previous reported work [12](#ene13919-bib-0012){ref-type="ref"}, [13](#ene13919-bib-0013){ref-type="ref"}. Meanwhile, the prevalence of apathy (14.8%) and hyperhidrosis (2.6%) is significant lower than in other studies. The variability in reported prevalence rate of pNMS may be due to individual\'s perception and reporting of NMS. Many NMS progress slowly and are of mild severity, so are underappreciated in the early stages [12](#ene13919-bib-0012){ref-type="ref"}. Furthermore, cognitive impairment has also been associated with underestimation of NMS and loss of awareness of hyposmia has been reported to occur in Parkinson's disease mild cognitive impairment [18](#ene13919-bib-0018){ref-type="ref"}. It is possible that cognitive performance may have impacted on symptom recall in our study as the mean Montreal Cognitive Assessment score was 25.2 (±3.7) and previously published work from the ICICLE‐PD study showed that, among the five cognitive domains, memory impairment was the most common domain affected in participants with PD at 1.5 SDs below normative values (15.1%) [5](#ene13919-bib-0005){ref-type="ref"}. However, all participants enrolled in the study underwent rigorous assessment to exclude dementia.

Gender has been reported as an independent predictor of NMS reported in early PD studies. Females have been reported to experience more anxiety, pain, depression and sleep disturbance [19](#ene13919-bib-0019){ref-type="ref"}, [20](#ene13919-bib-0020){ref-type="ref"}, [21](#ene13919-bib-0021){ref-type="ref"}, whereas males have been reported to experience more apathy and sexual dysfunction [22](#ene13919-bib-0022){ref-type="ref"}, [23](#ene13919-bib-0023){ref-type="ref"}, [24](#ene13919-bib-0024){ref-type="ref"}. However, there is a paucity of work examining the influence of gender on NMS in the prodromal period. We found a gender difference in terms of specific pNMS experienced, namely sexual dysfunction, forgetfulness and dream re‐enactment being more prevalent in males, and unexplained weight change and anxiety being more prevalent in females. Gender differences in perceived pNMS prevalence may be reflective of what each gender interprets to be important rather than any underlying early pathological evolutionary difference between genders.

There are some limitations in our study. The retrospective design of this study may have introduced recall error and thereby affected the accuracy of the data. Attempts were made to minimize recall errors by having experienced movement disorder physicians conduct face‐to‐face interviews with patients with recently diagnosed PD, including a caregiver interview. Another limitation is the lack of a validated prodromal questionnaire to evaluate pNMS. NMSQuest was adapted to identify pNMS as is has been extensively used to investigate NMS in *de‐novo*, early PD. However, its sensitivity and specificity for evaluating prodromal symptoms in 'at risk' PD cohorts have not been established. Therefore, it is entirely possible that some of the symptoms reported in this study are not related to an evolving Lewy body disorder but other underlying medical conditions or non‐specific normal age‐related symptoms.

In conclusion, our study has shown that pNMS are prevalent, antedate motor symptoms in some cases by several years and distinct gender differences exist in the pNMS experienced. Furthermore, prodromal GI and urinary tract symptoms were associated with the PIGD motor phenotype.
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###### 

**Table S1.** Logistic regression of predictors of PIGD phenotype versus TD phenotype.

###### 

Click here for additional data file.
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